What is 3SBio?
Founded in 1993 and headquartered in Liaoning, China, 3SBio operates as a fully-integrated biotechnology company. Its biopharmaceutical franchises span critical areas including oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. The company's comprehensive approach integrates research, development, manufacturing, and commercialization, aiming to address significant unmet medical needs within China and potentially global markets.
3SBio's established presence and diverse portfolio indicate a mature stage in its development, likely leveraging its extensive experience to drive innovation and market penetration.
How much funding has 3SBio raised?
3SBio has raised a total of $712M across 1 funding round:
Stock Offering
$712M
Stock Issuance/Offering (2015): $712M, investors not publicly disclosed
What's next for 3SBio?
With the recent infusion of capital, 3SBio is poised to accelerate its strategic objectives. This major investment is expected to fuel advancements in its existing biopharmaceutical franchises, potentially enabling the expansion of clinical trials, enhancement of manufacturing capabilities, and the pursuit of new drug development opportunities. The company's focus on oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology suggests a strategic allocation of resources towards areas with high growth potential and significant patient impact.
Future developments may include strategic partnerships, further pipeline expansion, and increased market outreach, solidifying 3SBio's position as a key player in China's rapidly evolving biotechnology landscape.
